Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences’ Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2023. The selected abstracts presented in partnership with Gilead Sciences highlight the company’s expanding portfolio of investigational medicines and late-stage studies across multiple types of cancer, including lung, upper GI and kidney cancer.

“The Arcus and Gilead abstracts that will be presented in June highlight the size and breadth of our portfolio and development program and include four of our investigational medicines being studied across multiple types of cancer,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. “The update from the ARC-7 study will include an analysis of all 150 efficacy-evaluable participants. The TIPs highlight our broad, late-stage domvanalimab program in lung and upper GI cancer, and our newest molecule, AB521, being studied in kidney cancer and other solid tumors.”

Seven Accepted Abstracts Will Be Presented

Study	Title	Abstract Number	Session Type & Title	Session Date & Time
domvanalimab (Fc-silent anti-TIGIT monoclonal antibody)
ARC-7	ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)	397600	Primary Track: Special Sessions	June 3, 2023, session start time: 12:30 PM CT
VELOCITY-Lung Sub Study-01 TIP	VELOCITY-Lung: A Phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).	TPS9155	Poster Session - Lung Cancer—Non-Small Cell Metastatic	6/4/2023, 8:00 AM-11:00 AM CT